Condition
Relapsed/Refractory Autoimmune Diseases
Total Trials
5
Recruiting
4
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
Early P 1 (3)
P 1 (1)
Trial Status
Recruiting4
Withdrawn1
Clinical Trials (5)
Showing 5 of 5 trials
NCT07448298Early Phase 1RecruitingPrimary
A Clinical Study of AFN50 in the Treatment of Autoimmune Diseases
NCT07095075Early Phase 1RecruitingPrimary
A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases
NCT07049081Phase 1RecruitingPrimary
A Study of LUCAR-G79 in Subjects With Relapsed/Refractory Autoimmune Diseases
NCT07193667Not ApplicableRecruitingPrimary
CAR-T in Subjects With Relapsed/Refractory Autoimmune Disease
NCT06866080Early Phase 1WithdrawnPrimary
A Study of LCAR-AIO in Subjects With Relapsed/Refractory Autoimmune Diseases
Showing all 5 trials